

# Special Issue

## High Risk Gynecological Cancers

### Message from the Guest Editors

This Special Issue of *Cancers* calls for contributions from the translational research field with a focus on cancers that initiate in the female genital tract and that resist standard therapies. Cancers of the uterine cervix, the endometrium, or the ovary have a total incidence of 1.2 Million per year worldwide and a major impact on mortality in women of all age categories. For this Special Issue, we welcome manuscripts that provide translational information on the topics mentioned above, with a focus on high-risk cervical, endometrial, and ovarian cancers. We will also consider manuscripts that provide translational information on other gynecological cancer types with a lesser incidence.

### Guest Editors

Dr. Suzy Marie E. Scholl

Department of drug development and innovation, Institut Curie, Paris, France

Dr. Eva Colas

Group of Biomedical Research in Gynecology, Vall Hebron Institute of Research, Barcelona, Spain

### Deadline for manuscript submissions

closed (1 October 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/52194](https://mdpi.com/si/52194)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)